Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS

https://cardiab.biomedcentral.com/articles/10.1186/s12933-019-0921-2

To examine the effects of the DPP-4i sitagliptin on CV outcomes during and after incident MI in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).

Ryan
Ryan

No Comments

Write a Reply or Comment